Stronger Sell Today AGIO ranks #3940 as SELL CANDIDATE #3940 Weaker Sell

AGIO stock forecast Agios Pharmaceuticals

AGIO stock forecast

Wednesday May 22, 2019 Change -0.02% Price $51.35
Chart period: 2019-02-25 - 2019-05-22
VOLUME
Sell
TREND
Sell
MV LONG
Sell

MV SHORT
Buy

PIVOT
Sell

MACD
Buy

Will AGIO stock price go up or down on Thu, 23 May 2019?

Predict

Agios Pharmaceuticals Forecast and Stock Analysis

Technical AGIO stock analysis for Wednesday May 22, 2019.

Sell candidate since 2019-04-30 Loss -8.17%
Shorts n/a
Insider % n/a
Institutional % n/a
Beta 1.77
ROA -37.40%
Price to book USD 4.60
P/E Ratio -8.57
Next Earnings Date 2019-08-08


Agios Pharmaceuticals fell by -0.02% in the last day ( Wednesday, 22nd May 2019 ) from $51.36 to $51.35 During day the stock fluctuated 3.34% from a day low at $50.33 to a day high of $52.01. The price has fallen in 6 of the last 10 days and is down by -0.58% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -52 093 shares and in total 420 739 shares bought and sold for approximately $21.60 million.

Quick summary:

  • 30 day high of the AGIO stock price was $59.53 and low was $46.31.
  • 90 day high was $68.94 and low was $46.31.
  • 52 week high for the Agios Pharmaceuticals - $99.82 and low - $41.63.

Trend

Agios Pharmaceuticals lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.28% during the next 3 months and, with 90% probability hold a price between $33.73 and $44.14 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

Some negative signals were issued as well, and these may have some influence on the near short-term development. Agios Pharmaceuticals holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $55.99. On a fall, the stock will find some support from the short-term average at $49.48. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. A sales signal was issued from a pivot top point on Tuesday May 21, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 50 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Agios Pharmaceuticals finds support from accumulated volume at $50.47.

Support: $50.47 Price: $51.35 Resistance: $51.50

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.68 between high and low, or 3.34%. For the last week, the stock has had a daily average volatility of 6.17%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

6.17 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Stronger Sell Today AGIO ranks #3940 as SELL CANDIDATE #3940 Weaker Sell
AGIO $51.35 ($-0.01 -0.02%)
AGIO is down $0.01 today, but where's it headed in 2019?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month system that more than doubles the S&P 500.

This report is free today for StockInvest.us readers.

Click here – the AGIO analysis is free »

Will AGIO stock price go up or down
on Thu, 23 May 2019?

Predict

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank